Osaka To Collaborate With Shanghai On Biotechnology Exchange
This article was originally published in PharmAsia News
The governments of Osaka Prefecture and Shanghai will sign a collaborative agreement to promote biotechnology exchange. The two sides could reach an agreement by November. Osaka's governor is visiting Shanghai to tour Zhangjiang Hi-Tech Park, and he will negotiate with his counterparts in Shanghai on details of the agreement. Osaka and Shanghai have hosted trade fairs for pharmaceutical companies from both countries in the past two years, and now both sides want to further collaboration and expand marketing channels for Chinese and Japanese biotech companies. (Click here for more - Japanese language)
You may also be interested in...
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.